Cytokinetics INC

Cytokinetics, Inc. reported on its 2026 Annual Meeting of Stockholders, where directors were elected, an employee stock purchase plan was amended, and the independent auditor was ratified.

Cytokinetics, Inc. has finalized a public offering of common stock, raising approximately $760.2 million to bolster its financial position.

Cytokinetics, Inc. provided a corporate presentation detailing its approved products, pipeline advancements, and financial position, highlighting progress in cardiovascular and neuromuscular diseases.

Cytokinetics announced strong first quarter 2026 financial results, driven by the successful U.S. launch of MYQORZO and positive clinical trial updates.

Cytokinetics announced its Q4 and full-year 2025 financial results, highlighting the successful U.S., China, and Europe approvals and launch of MYQORZO for oHCM, alongside 2026 financial guidance.

The European Commission has granted approval for Cytokinetics' MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients.

Cytokinetics, Inc. filed its Q1 2026 10-Q report, detailing financial performance, progress on MYQORZO commercialization, and ongoing clinical development programs.

Cytokinetics reports increased net loss and R&D expenses in Q3 2025, with aficamten's FDA PDUFA date extended to December 26, 2025, due to REMS submission.

Cytokinetics reports significant revenue growth from new collaborations and positive clinical trial results for Aficamten, despite increased operating losses and a PDUFA date extension.

Cytokinetics reports a net loss of $161.4 million for Q1 2025, with key updates on aficamten's regulatory pathway and ongoing clinical trials.

Cytokinetics' third quarter 2024 report details financial results and provides updates on key clinical programs, including aficamten and omecamtiv mecarbil.

Cytokinetics' second quarter 2024 filing details financial results, ongoing research and development activities, and recent financing transactions.

Cytokinetics reports FDA, EU, and China approvals for MYQORZO (aficamten) for oHCM, while advancing its cardiology and neuromuscular pipeline and facing significant financial losses.

Cytokinetics' 2024 10-K filing highlights the acceptance of the aficamten NDA, progress in the omecamtiv mecarbil COMET-HF trial, and strategic collaborations to advance its muscle biology-focused pipeline.

Cytokinetics' 10-K filing reveals a year of significant R&D investment and strategic positioning for potential commercial launches, alongside ongoing regulatory challenges.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 14,000 shares of common stock on July 30, 2026 for $79.88 per share.

Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 27, 2026 for $80.87 per share.

Fady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on July 21, 2026 for $80.59 per share.

Nancy Wysenski, a Director of Cytokinetics Inc, received 75 shares of common stock on July 15, 2026.

Wendell Wierenga, a Director of Cytokinetics Inc, received 75 shares of common stock on July 15, 2026.

Edward M. Kaye, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.

Cytokinetics, Inc. has issued its 2026 Proxy Statement detailing proposals for the upcoming Annual Meeting of Stockholders on May 27, 2026.

Cytokinetics is asking stockholders to approve proposals at its upcoming annual meeting, including increasing authorized shares and amending its equity incentive plan.

Cytokinetics has filed its proxy statement for the 2024 Annual Meeting of Stockholders, outlining proposals for director elections, an employee stock purchase plan amendment, ratification of auditors, and an advisory vote on executive compensation.

FMR LLC, through its subsidiaries and affiliates, has disclosed beneficial ownership of 5,248,579.71 shares, representing 3.9% of the outstanding common stock of Cytokinetics Inc., as of June 30, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 9.0% of Cytokinetics Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.21% beneficial ownership stake in Cytokinetics Inc.

The Vanguard Group has reported a 0% beneficial ownership in Cytokinetics Inc. following an internal realignment.

T. Rowe Price Investment Management, Inc. reported an amended beneficial ownership of 16.0% in Cytokinetics Inc., holding 19,097,373 common shares.

State Street Corporation has filed a Schedule 13G, reporting a 4.7% beneficial ownership stake in Cytokinetics Inc. common stock as of September 30, 2025.